


WE CLAIM:

1. A compound of formula I



I


or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

5 n is 1-3;

10 R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

SEARCHED INDEXED
SERIALIZED FILED
APR 24 1970

Sub
A'



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

5 R_2 is selected from the group consisting of hydrogen, C_1-C_9 , straight or branched chain alkyl, C_2-C_9 , straight or branched chain alkenyl, C_2-C_9 , straight or branched chain alkynyl, aryl,

heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃;

5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, 10 sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

15 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or 20 heterocycle group; and

X is O or S.

2. The compound of claim 1, wherein the compound is non-immunosuppressive.

25 3. The compound of claim 1, wherein said compound is selected from the group consisting of:

Sub C1 3,3-dimethyl-N-[2-(5-phenylpentanoyl)-tetrahydro-1H-1-pyrazolyl]-1,2-pentanedione;

3,3-dimethyl-N-[2-(3-phenylpropanoyl)tetrahydro-1H-1-pyrazolyl]-1,2-pentanedione;

3,3-dimethyl-1-[2-(5-(3-pyridyl)pent-4-ynoyl)-pyrazolidinyl]pentane-1,2-dione;

5 3,3-dimethyl-1-[2-(5-(cyano)pent-4-ynoyl)pyrazolidinyl]-pentane-1,2-dione;

Sub
Cl
10 3,3-dimethyl-1-[2-(4-phenylbutanoyl)pyrazolidinyl]-pentane-1,2-dione;

10 3,3-dimethyl-1-[2-(6-phenylhexanoyl)pyrazolidinyl]-pentane-1,2-dione;

15 3,3-dimethyl-1-[2-(5-(3-pyridyl)pentanoyl)-pyrazolidinyl]pentane-1,2-dione;

3-phenylpropyl 2-(3,3-dimethyl-2-oxopentanoyl)-pyrazolidinecarboxylate;

15 3-(3-pyridyl)propyl 2-(3,3-dimethyl-2-oxopentanoyl)-pyrazolidinecarboxylate;

4-phenylbutyl 2-(3,3-dimethyl-2-oxopentanoyl)-pyrazolidinecarboxylate;

20 2-phenylethyl 2-(3,3-dimethyl-2-oxopentanoyl)-pyrazolidinecarboxylate;

3,3-dimethyl-1-[2-(6-phenylhexanoyl)perhydro-pyridazinyl]pentane-1,2-dione;

3,3-dimethyl-1-[2-(6-(3-pyridyl)hexanoyl)-perhydropyridazinyl]pentane-1,2-dione;

25 3-phenylpropyl 2-(3,3-dimethyl-2-oxopentanoyl)-perhydropyridazinecarboxylate;

4-phenylbutyl 2-(3,3-dimethyl-2-oxopentanoyl)-perhydropyridazinecarboxylate;

5-phenylpentyl 2-(3,3-dimethyl-2-oxopentanoyl)-
perhydropyridazinecarboxylate;

4-(3-pyridyl)butyl 2-(3,3-dimethyl-2-oxopentanoyl)-
perhydropyridazinecarboxylate;

5 3,3-dimethyl-1-[2-(5-phenylpentanoyl)perhydro-
pyridazinyl]pentane-1,2-dione; and


pharmaceutically acceptable salts, esters and solvates
thereof.

10

4. A pharmaceutical composition comprising:

(i) a therapeutically effective amount of a compound of
formula I:

Sub
A²




15

or a pharmaceutically acceptable salt, ester or solvate
thereof, wherein:

n is 1-3;

20

R₁ is selected from the group consisting of -CR₃, -COOR₃,
-COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -
SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -
COHNSO₂R₃, -CONR₃CN,



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R_2 is selected from the group consisting of hydrogen, C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, aryl,

Sub A2

heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃;

5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ 10 alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

15 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or 20 heterocycle group; and

X is O or S; and

(ii) a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of claim 4, further comprising an additional neurotrophic factor.

Sub C1

25 6. The pharmaceutical composition of claim 5, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor,

Sub

C1

insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factor, neurotropin-3, neurotropin-4 and neurotropin-5.


5

7. A method for effecting a neuronal activity in a mammal, comprising administering to the mammal an effective amount of a compound of formula I:

Sub

A3

I



10


or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

15

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

DOCUMENT EVIDENCE
P. 102

Sub
A3

wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R_2 is selected from the group consisting of hydrogen, C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, aryl,

Sub A³

heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃;

5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ 10 alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

15 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or 20 heterocycle group; and

X is O or S.

8. The method of claim 7, wherein the neuronal activity is selected from the group consisting of stimulation of 25 damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.

Sub C¹

9. The method of claim 8, wherein the neurological disorder is selected from the group consisting of peripheral 30

neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and a neurological disorder relating to neurodegeneration.


5

10. The method of claim 11, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

10

11. A compound of formula II:

II




or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

15

n is 1-3;

R_1 is selected from the group consisting of $-CR_3$, $-COOR_3$, $-COR_3$, $-COOH$, $-SO_3H$, $-SO_2HNR_3$, $-PO_2(R_3)_2$, $-CN$, $-PO_3(R_3)_2$, $-OR_3$, $-SR_3$, $-NHCOR_3$, $-N(R_3)_2$, $-CON(R_3)_2$, $-CONH(O)R_3$, $-CONHNHSO_2R_3$, $-COHSO_2R_3$, $-CONR_3CN$,

Sub
A4



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R_2 is selected from the group consisting of hydrogen, C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, aryl,

Suh
A4

heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃; and

5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

10 15 20 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group.

Suh
Cl

12. The compound of claim 11, wherein the compound is non-immunosuppressive.

25 13. The compound of claim 11, which is selected from the group consisting of:

3-phenylpropyl carboxylate; 2-[benzylsulfonyl]pyrazolidine-

30 4-phenylbutyl carboxylate; 2-[benzylsulfonyl]perhydropyridazine-


Sub
C 1
1- (5-phenylpentanoyl)-2-(benzylsulfonyl)tetrahydro-1H-1-pyrazole; and

pharmaceutically acceptable salts, esters and solvates thereof.

5

14. A pharmaceutical composition comprising:

(i) a therapeutically effective amount of a compound of formula III:




10 or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

15 R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

Sub
AS



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R_2 is selected from the group consisting of hydrogen, C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, aryl,

heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R_3 ; and

5 R_3 is selected from the group consisting of hydrogen, C_1-C_9 , alkyl, C_2-C_9 , straight or branched chain alkenyl, C_2-C_9 , straight or branched chain alkynyl, C_1-C_9 , alkoxy, C_2-C_9 , alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C_1-C_9 , thioalkyl, C_2-C_9 , thioalkenyl, C_1-C_9 , alkylamino, C_2-C_9 , alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulphydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group; and


(ii) a pharmaceutically acceptable carrier.

15. The pharmaceutical composition of claim 14, further comprising an additional neurotrophic factor.

25
b
1
30 16. The pharmaceutical composition of claim 15, wherein
the additional neurotrophic factor is selected from the group
consisting of neurotrophic growth factor, brain derived growth
factor, glial derived growth factor, ciliary neurotrophic factor,
insulin growth factor, acidic fibroblast growth factor, basic

fibroblast growth factor, platelet-derived growth factor, neurotropin-3, neurotropin-4 and neurotropin-5.


5 17. A method for effecting a neuronal activity in a mammal, comprising administering to the mammal an effective amount of a compound of formula II:



10 or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HN R₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

S
S
Cl

wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

5 R_2 is selected from the group consisting of hydrogen, C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, aryl,

Suj Cl
heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃; and

5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

10 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group.


15 18. The method of claim 17, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.

20 19. The method of claim 18, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state,

traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and a neurological disorder relating to neurodegeneration.

5 20. The method of claim 19, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

10 21. A compound of formula III:




III

or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

15 R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

Sub
C1



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

5 R and R₂ are independently C₁-C₉ alkyl, C₂-C₉ alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle

is unsubstituted or substituted with one or more substituent(s) selected from R₃; and

R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group.


20 22. The compound of claim 21, wherein the compound is non-immunosuppressive.

25 23. The compound of claim 21, wherein said compound is 1-(5-phenylpentanoyl)-2-(N,N-dicyclohexylcarbamoyl)-tetrahydro-1H-1-pyrazole or a pharmaceutically acceptable salt, ester or solvate thereof.

24. A pharmaceutical composition comprising:

(i) a therapeutically effective amount of a compound of

formula III:



III


Suj
Cl

or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

5 n is 1-3;

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHSO₂R₃, -CONR₃CN,

SUCI



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R and R_2 are independently C_1-C_9 alkyl, C_2-C_9 alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle

is unsubstituted or substituted with one or more substituent(s) selected from R₃; and

R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,


wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group; and

(ii) a pharmaceutically acceptable carrier.

25. The pharmaceutical composition of claim 24, further comprising an additional neurotrophic factor.

26. The pharmaceutical composition of claim 25, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neurotrophic factor, insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factor, neurotropin-3, neurotropin-4 and neurotropin-5.


27. A method for effecting a neuronal activity in a mammal, comprising administering to the mammal an effective amount of a compound of formula III:



5 or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

10 R_1 is selected from the group consisting of $-CR_3$, $-COOR_3$, $-COR_3$, $-COOH$, $-SO_3H$, $-SO_2HNR_3$, $-PO_2(R_3)_2$, $-CN$, $-PO_3(R_3)_2$, $-OR_3$, $-SR_3$, $-NHCOR_3$, $-N(R_3)_2$, $-CON(R_3)_2$, $-CONH(O)R_3$, $-CONHNHSO_2R_3$, $-COHNSO_2R_3$, $-CONR_3CN$,

Sub
Cl

wherein said R_1 group is either unsubstituted or substituted with one or more substituent(s);

5 R and R_2 are independently C_1-C_9 alkyl, C_2-C_9 alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle

is unsubstituted or substituted with one or more substituent(s); and

R_3 is selected from the group consisting of hydrogen, C_1-C_9 alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, C_1-C_9 alkoxy, C_2-C_9 alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C_1-C_9 thioalkyl, C_2-C_9 thioalkenyl, C_1-C_9 alkylamino, C_2-C_9 alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulphydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle.

wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group.


28. The method of claim 27, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration, and treatment of a neurological disorder.

29. The method of claim 28, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and a neurological

disorder relating to neurodegeneration.

Sub
C1 5
30. The method of claim 29, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.


31. A compound of formula IV:



n is 1-3;

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

35
cont



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ; and

5 R_2 is C_1-C_9 alkyl, C_2-C_9 alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle is substituted with one

or more substituent(s) selected from R_3 ; and

*BS
cont*

R_3 is selected from the group consisting of hydrogen, C_1-C_9 alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, C_1-C_9 alkoxy, C_2-C_9 alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C_1-C_9 thioalkyl, C_2-C_9 thioalkenyl, C_1-C_9 alkylamino, C_2-C_9 alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulphydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

10 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulphydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group.

20 32. The compound of claim 31, wherein the compound is non-immunosuppressive.

*Su
Cl*

33. The compound of claim 31, wherein said compound is selected from the group consisting of:

25 3-phenylpropyl 2-(*N*-cyclohexylcarbamoyl)pyrazolidine-carboxylate;


4-phenylbutyl 2-(*N*-cyclohexylcarbamoyl)perhydro-pyridazinecarboxylate;

1-(5-phenylpentanoyl)-2-(*N*-cyclohexylcarbamoyl)-tetrahydro-1*H*-1-pyrazole; and

pharmaceutically acceptable salts, esters and solvates thereof.

34. A pharmaceutical composition comprising:


5 (i) a therapeutically effective amount of a compound of formula IV:



n is 1-3;

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

Sub
Cl



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ; and

R₂ is C₁-C₉ alkyl, C₂-C₉ alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle is substituted with one

or more substituent(s) selected from R₃; and

R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,


wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group; and

(ii) a pharmaceutically acceptable carrier.

35. The pharmaceutical composition of claim 34, further comprising an additional neurotrophic factor.

36. The pharmaceutical composition of claim 35, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, ciliary neutrophic factor, insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factor, neurotropin-3, neurotropin-4 and neurotropin-5.

37. A method for effecting a neuronal activity in a mammal, comprising administering to the mammal an effective amount of a compound of formula IV:




IV

5 or a pharmaceutically acceptable salt, ester or solvate
thereof, wherein:

n is 1-3;

R_1 is selected from the group consisting of $-CR_3$, $-COOR_3$, $-COR_3$, $-COOH$, $-SO_3H$, $-SO_2HNR_3$, $-PO_2(R_3)_2$, $-CN$, $-PO_3(R_3)_2$, $-OR_3$, $-SR_3$, $-NHCOR_3$, $-N(R_3)_2$, $-CON(R_3)_2$, $-CONH(Q)R_3$, $-CONHNHSO_2R_3$, $-COHSO_2R_3$, $-CONR_3CN$,

卷之三



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ; and

R_2 is C_1 - C_9 alkyl, C_2 - C_9 alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle is substituted with one

or more substituent(s) selected from R₃; and

R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group.

38. The method of claim 37, wherein the neuronal activity is selected from the group consisting of stimulation of damaged neurons, promotion of neuronal regeneration, prevention of neurodegeneration and treatment of a neurological disorder.


39. The method of claim 38, wherein the neurological disorder is selected from the group consisting of peripheral neuropathy caused by physical injury or disease state, traumatic injury to the brain, physical damage to the spinal cord, stroke associated with brain damage, and a neurological disorder relating to neurodegeneration.

Sub C1

40. The method of claim 39, wherein the neurological disorder relating to neurodegeneration is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis.

5

41. A process for preparing a compound having the formula (I):




or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,

10

15



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R_2 is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, aryl,

heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃;


5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, 10 sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,

15 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or 20 heterocycle group; and

X is O,

which process comprises (1):

(a) reacting a compound of the formula:




25 with a compound of the formula R₂-Mg-X, wherein

~~R'~~ is a straight or branched chain alkyl group which is optionally substituted in one or more positions;

~~X~~ is halogen; and

~~n~~, ~~R₃~~, and ~~R₂~~ are as defined above; or


5 (b) reacting a compound of the formula:



with a compound of the formula R_3COOH or activated derivatives thereof, wherein

~~n~~, ~~R₃~~, and ~~R₂~~ are as defined above; or

10 (c) reacting a compound of the formula:



with a compound of the formula R_2-Mg-X , wherein


~~R'~~ is a straight or branched chain alkyl group which is optionally substituted in one or more positions;

15 R_4 is an alkyl group substituted with an aryl group;

X is halogen; and

n and R_2 are as defined above; or

(d) reducing a compound of the formula:




wherein

n and R₂ are as defined above,

and, if desired,

5 (2) removing a protecting group from the product.

42. A process for preparing a compound having the formula (II):




II

10 or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ;

R_2 is selected from the group consisting of hydrogen, C_1-C_9 straight or branched chain alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, aryl,


heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, carbocycle, or heterocycle is unsubstituted or substituted with one or more substituents selected from R₃; and

5 R₃ is selected from the group consisting of hydrogen, C₁-C₉ alkyl, C₂-C₉ straight or branched chain alkenyl, C₂-C₉ straight or branched chain alkynyl, C₁-C₉ alkoxy, C₂-C₉ alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C₁-C₉ thioalkyl, C₂-C₉ thioalkenyl, C₁-C₉ alkylamino, C₂-C₉ 10 alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,


15 wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or 20 heterocycle group,

which process comprises (1):

reacting a compound of the formula:



with a compound of the formula:



wherein


X is halogen; and

n, R₃, and R₂ are as defined above,

and, if desired,

5 (2) removing a protecting group from the product.

43. A process for preparing a compound having the formula (IV):




IV

10 or a pharmaceutically acceptable salt, ester or solvate thereof, wherein:

n is 1-3;

15 R₁ is selected from the group consisting of -CR₃, -COOR₃, -COR₃, -COOH, -SO₃H, -SO₂HNR₃, -PO₂(R₃)₂, -CN, -PO₃(R₃)₂, -OR₃, -SR₃, -NHCOR₃, -N(R₃)₂, -CON(R₃)₂, -CONH(O)R₃, -CONHNHSO₂R₃, -COHNSO₂R₃, -CONR₃CN,



wherein said R_1 group is either unsubstituted or additionally substituted with R_3 ; and

5 R_2 is C_1-C_9 alkyl, C_2-C_9 alkenyl, aryl, heteroaryl, carbocycle, or heterocycle, wherein said alkyl, alkenyl, aryl, heteroaryl, carbocycle, or heterocycle is substituted with one


or more substituent(s) selected from R_3 ; and

R_3 is selected from the group consisting of hydrogen, C_1-C_9 alkyl, C_2-C_9 straight or branched chain alkenyl, C_2-C_9 straight or branched chain alkynyl, C_1-C_9 alkoxy, C_2-C_9 alkenyloxy, aryloxy, phenoxy, benzyloxy, hydroxy, carboxy, C_1-C_9 thioalkyl, C_2-C_9 thioalkenyl, C_1-C_9 alkylamino, C_2-C_9 alkenylamino, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, and heterocycle,


wherein said alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy, aryloxy, thioalkyl, thioalkenyl, alkylamino, alkenylamino, aryl, heteroaryl, carbocycle, or heterocycle group is optionally substituted with a hydroxy, carboxy, carbonyl, cyano, nitro, imino, sulfonyl, thiocarbonyl, sulfhydryl, halo, haloalkyl, trifluoromethyl, aryl, heteroaryl, carbocycle, or heterocycle group,

which process comprises (1):

reacting a compound of the formula:



with a compound of the formula:



wherein

n , R_3 , and R_2 are as defined above,

and, if desired,

(2) removing a protecting group from the product.

add

A6